Issue 1279: December 7, 2016

Ask the Experts
Ask the Experts—Question of the Week: For our "Mother's Day Out" program, one of the teachers has shingles…read more


TOP STORIES


IAC HANDOUTS


VACCINE INFORMATION STATEMENTS


WORLD NEWS


FEATURED RESOURCES


JOURNAL ARTICLES AND NEWSLETTERS



TOP STORIES


It's National Influenza Vaccination Week

This week is National Influenza Vaccination Week (NIVW). This event highlights the importance of continuing influenza vaccination throughout the season.

       

CDC published Announcement: National Influenza Vaccination Week—December 4–10, 2016 in the December 2 issue of MMWR (page 1353). The complete announcement is reprinted below.

The U.S. Department of Health and Human Services, CDC, state and local health departments, and other partners will observe National Influenza Vaccination Week during December 4–10, 2016, with educational and promotional activities across the country. Beginning in 2005, National Influenza Vaccination Week was established to highlight the importance of annual influenza vaccination and to foster greater use of influenza vaccine during the months of December, January, and beyond. Last season, almost half (45.6%) of the U.S. population aged ≥6 months are estimated to have received vaccination against influenza. This is a small decline of 1.5% since the previous season (47.1%), but close to what was seen during the 2013–2014 (46.2%).

As of November 10, 2016, approximately 129.2 million doses of 2016–17 seasonal influenza vaccine have been distributed to vaccination providers in the United States. The Advisory Committee on Immunization Practices (ACIP) recommends influenza vaccination for all persons aged ≥6 months, with rare exceptions. Because of its low effectiveness against influenza A(H1N1)pdm09 in the United States during the 2013–14 and 2015–16 seasons, ACIP made the interim recommendation that quadrivalent live attenuated influenza vaccine should not be used for the 2016–17 season.

Influenza vaccination is especially important for persons in certain groups who are at increased risk for influenza-related complications. Those persons at high risk include children aged <5 years, and especially children aged <2 years; persons with certain chronic health conditions, such as heart disease, asthma, and diabetes; pregnant women; and adults aged ≥65 years. Health care personnel are also at risk for acquiring and transmitting influenza to their patients. Information about events, web tools, and CDC's planned activities for National Influenza Vaccination Week are available at http://www.cdc.gov/flu/nivw/index.htm, and http://www.cdc.gov/flu/freeresources. Additional information and resources for health care professionals are available at http://www.cdc.gov/flu/professionals/index.htm. Influenza vaccination coverage estimates for 2015–16 are available at http://www.cdc.gov/flu/fluvaxview.

Related Links

Back to top


CDC posts updated HPV (Human Papillomavirus) Vaccine Information Statement

On December 2, CDC posted an updated HPV (Human Papillomavirus) Vaccine Information Statement (VIS). It is essentially the same as the VIS it replaces (dated 3/31/16), except that it contains information about the recently approved 2-dose schedule. Ideally, providers should begin using it now, but stocks of the previous edition may be used up, especially if you have patients who need the 3-dose schedule.

Note that the VIS no longer specifies “Gardasil-9.” This is because Gardasil-9 will soon be the only HPV vaccine available in the U.S., as Cervarix and Gardasil-4 will no longer be sold in the United States. The appropriate VISs should continue to be used for those two vaccines as long as unexpired doses remain available.

Related Links

Back to top


More than 300 birthing institutions are enrolled in IAC's Hepatitis B Birth Dose Honor Roll!


The Immunization Action Coalition (IAC) is pleased to announce that 13 new hospitals or birthing centers have been accepted into its Hepatitis B Birth Dose Honor Roll, for a total of 310! Nine of these birthing institutions applied and qualified for two 1-year periods at one time.

The new birthing institutions are listed below with their reported hepatitis B birth dose coverage rates in parentheses.
  • Ben Taub Hospital, Houston, TX (96% in 2014; 100% in 2015)
  • HCA The Women's Hospital of Texas, Houston, TX (93% in 2014; 98% in 2015)
  • Houston Methodist Hospital, Houston, TX (100% in 2014; 98% in 2015)
  • Houston Methodist St. John Hospital, Nassau Bay, TX (93% in 2014; 94% in 2015)
  • Lyndon B. Johnson General Hospital, Houston, TX (100% in 2014; 98% in 2015)
  • Memorial Hermann Southeast Hospital, Houston, TX (96% in 2014; 100% in 2015)
  • Memorial Hermann Southwest Hospital, Houston, TX (100% in 2014; 98% in 2015)
  • Methodist San Jacinto Hospital, Baytown, TX (100% in 2014; 100% in 2015)
  • MidState Medical Center, Meriden, CT (98%)
  • Sagua Managu, Tamuning, GU (100% in 2014; 100% in 2015)
  • Texas Children's Hospital, Houston, TX (92%)
  • The Hospital of Central Connecticut, New Britain, CT (91%)
  • Tomball Regional Medical Center, Tomball, TX (98%)

The following institution is being recognized for a third year:

  • Queens Hospital Center, Queens, NY (99%)

The Honor Roll now includes 310 birthing institutions from 38 states, Puerto Rico, and Guam. Ninety-five institutions have qualified for two years, 35 institutions have qualified three times, 5 institutions have qualified four times, and 2 institutions have qualified five times.

With these additions, our Honor Roll list now numbers more than 300 birthing institutions. To celebrate, we have been given permission to share this special photograph from Guam Medical Hospital Authority, Oka Tamuning, Guam. The staff is proudly showing off the five certificates they have earned for being on the Hepatitis B Birth Dose Honor Roll in 2011, 2012, 2013, 2014, and 2015.


The Honor Roll is a key part of IAC’s major initiative urging the nation’s hospitals to Give birth to the end of Hep B. Hospitals and birthing centers are recognized for attaining high coverage rates for administering hepatitis B vaccine at birth and meeting specific additional criteria. The initiative urges qualifying healthcare organizations to apply for the Hepatitis B Birth Dose Honor Roll online.

To be included in the Hepatitis B Birth Dose Honor Roll, a birthing institution must have: (1) reported a coverage rate of 90 percent or greater, over a 12-month period, for administering hepatitis B vaccine before hospital discharge to all newborns, including those whose parents refuse vaccination, and (2) implemented specific written policies, procedures, and protocols to protect all newborns from hepatitis B virus infection prior to hospital discharge.

Honorees are also awarded an 8.5" x 11" color certificate suitable for framing and their acceptance is announced to IAC Express’s approximately 50,000 readers.

Please visit the Hepatitis B Birth Dose Honor Roll web page that lists these institutions and their exceptional efforts to protect infants from perinatal hepatitis B transmission.

Related Links

Back to top


AAP develops a new interactive infographic that highlights immunization rates for DTaP, MMR, varicella, HPV, and influenza vaccines in each state

The American Academy of Pediatrics (AAP) recently released a new interactive infographic that highlights immunization rates for DTaP, MMR, varicella, HPV, and influenza vaccines in each state, as well as the combined 7-vaccine series for ages 19–35 months. It also lists individual state laws regarding exemptions, and highlights recent outbreaks of infectious diseases.

Related Links

Back to top


World AIDS Day was December 1; people with AIDS and HIV infection are at high risk for influenza-related complications and should be vaccinated

December 1 was World AIDS Day. The first paragraph of a CDC press release is reprinted below.

Today is World AIDS Day, a day to unite in the fight against HIV, support people living with HIV, and honor those who have lost their lives. This year’s theme,Leadership. Commitment. Impact., asks each of us to strengthen our commitment to stop HIV using the most up-to-date, evidence-based HIV interventions, prevention tools, and testing options available. In 2015, 39,513 people received a diagnosis of HIV, and over 1.2 million people are living with HIV in the United States.

People with HIV and AIDS are at high risk of serious influenza-related complications. According to CDC's website, studies done before routine use of highly active antiretroviral therapy suggested an increased risk for heart- and lung-related hospitalizations in people infected with HIV during influenza season as opposed to other times of the year, and a higher risk of influenza-related death in HIV-infected people. People with HIV and AIDS should get the inactivated influenza vaccine. It’s also important that influenza antiviral drugs be used early to treat influenza in people who are very sick (e.g., people who are in the hospital) and people who are sick with influenza and who have a greater chance of getting serious flu complications, such as people with HIV and AIDS.

Related Links

Back to top


IAC HANDOUTS


IAC develops new educational piece for healthcare professionals, “Meningococcal B Vaccine: CDC Answers Your Questions”

IAC recently developed a new educational piece for healthcare professionals titled Meningococcal B Vaccine: CDC Answers Your Questions. This 2-page piece covers some of the more common questions about meningococcal serogroup B vaccine with answers from experts at CDC.

IAC's Handouts for Patients & Staff web section offers healthcare professionals and the public more than 250 FREE English-language handouts (many also available in translation), which we encourage website users to print out, copy, and distribute widely.

Back to top


IAC updates “Meningococcal Vaccine Recommendations by Age and Risk Factor for Serogroup B Protection” as well as "Meningococcal Vaccine Recommendations by Age and Risk Factor for Serogroups A,C,W, or Y Protection"

IAC recently updated Meningococcal Vaccine Recommendations by Age and Risk Factor for Serogroup B Protection as well as Meningococcal Vaccine Recommendations by Age and Risk Factor for Serogroups A,C,W, or Y Protection.

Changes were made to the serogroup B education piece to incorporate the newest ACIP recommendation for vaccinating healthy teens using a 2-dose schedule with either of the two licensed MenB vaccines (Bexsero or Trumenba).

Changes were made to the second educational piece to incorporate the newest ACIP recommendations for vaccinating HIV-infected people with MenACWY vaccine.

Related Link

Back to top


IAC revises "Standing Orders for Administering Meningococcal ACWY Vaccine to Children and Teens" as well as "Standing Orders for Administering Meningococcal ACWY Vaccine to Adults"

IAC recently updated Standing Orders for Administering Meningococcal ACWY Vaccine to Children and Teens as well as Standing Orders for Administering Meningococcal ACWY Vaccine to Adults. Changes were made to incorporate the newest ACIP recommendation to vaccinate HIV-infected people with MenACWY vaccine.

Related Link

Back to top


IAC updates “Influenza Vaccine Products for the 2016–2017 Influenza Season”

IAC's Influenza Vaccine Products for the 2016–2017 Influenza Season was recently updated to& incorporate the FDA approval of an extended age range of FluLaval to include children age 6 through 35 months.

Related Link

Back to top


IAC updates “Decisions in the Omnibus Autism Proceeding”

IAC recently updated Decisions in the Omnibus Autism Proceeding to correct several broken links to the U.S. Court of Federal Claims website.

Related Link

Back to top


VACCINE INFORMATION STATEMENTS


Influenza (IIV) VIS now available in Chuukese, Ilokano, and Marshallese

IAC recently posted translations of the VIS inactivated influenza vaccine (IIV) in Chuukese, Ilokano, and Marshallese. IAC thanks the Hawaii Department of Health for the translations.

Related Links

Back to top


WORLD NEWS


WHO reports on the October meeting of the Strategic Advisory Group of Experts on Immunization in Weekly Epidemiological Report

The December 2 edition of the WHO periodical Weekly Epidemiological Record reported on the October 2016 meeting of the Strategic Advisory Group of Experts on Immunization in an article titled Meeting of the Strategic Advisory Group of Experts on immunization, October 2016—conclusions and recommendations.

Related Links

Back to top


FEATURED RESOURCES


Families Fighting Flu offers a new PSA in three different lengths

Families Fighting Flu (FFF) has developed a public service announcement (PSA) about protecting children from influenza with the theme "Play It Safe." This PSA is available in three lengths, as follows:   
You can also access this PSA and more on FFF's video web page.

Related Link

NFID releases reports and infographics about reducing the burden of influenza and RSV in older adults

The National Foundation for Infectious Diseases (NFID), recently shared new resources available to educate healthcare professionals about the burden of influenza and respiratory syncytial virus (RSV) in older adults. Materials developed include reports based on expert roundtables held this summer, Call to Action: Reinvigorating Influenza Prevention in US Adults Age 65+, and NFID Report: Respiratory Syncytial Virus in Older Adults: A Hidden Annual Epidemic, as well as infographics on both influenza and respiratory syncytial virus.

Related Links

Back to top


Influenza is spreading and serious; please keep vaccinating your patients

Influenza vaccination is recommended for everyone six months of age and older. If you don't provide influenza vaccination in your clinic, please recommend vaccination to your patients and refer them to a clinic or pharmacy that provides vaccines or to the HealthMap Vaccine Finder to locate sites near their workplaces or homes that offer influenza vaccination services.

Following is a list of resources related to influenza disease and vaccination for healthcare professionals and the public:

Back to top



JOURNAL ARTICLES AND NEWSLETTERS


CDC reports on adverse reaction after smallpox vaccination in New Mexico

CDC published Notes from the Field: Adverse Reaction After Vaccinia Virus Vaccination—New Mexico, 2016 in the December 2 issue of MMWR (pages 1351–52). An excerpt from the article is reprinted below.

On February 4, 2016, the New Mexico Department of Health (NMDOH) was contacted regarding a patient who had received ACAM2000 smallpox (vaccinia) vaccine 12 days earlier as part of an institutional review board–approved study at a plasma donation center and had numerous lesions surrounding the inoculation site and on the opposite arm, back, and abdomen. ACAM2000 is a live-virus vaccine indicated for active immunization against smallpox...

Back to top



ASK THE EXPERTS

Question of the Week

For our "Mother's Day Out" program, one of the teachers has shingles. The program serves moms of 2-month-olds to 4-year-olds. All children are up to date with their vaccinations, but some are too young to have received varicella vaccine. Is it safe for the teacher to work?

In a school setting, an immunocompetent person with zoster (staff or students) can remain at school as long as the lesions can be completely covered. People with zoster should be careful about personal hygiene, wash their hands after touching their lesions, and avoid close contact with others. If the lesions cannot be completely covered and close contact avoided, the person should be excluded from the school setting until the zoster lesions have crusted over. See www.cdc.gov/chickenpox/outbreaks/manual.html for more information.

If your program is licensed by a state or county, you should check their regulations as well.


About IAC's Question of the Week

Each week, IAC Express highlights a new, topical, or important-to-reiterate Q&A. This feature is a cooperative venture between IAC and CDC. William L. Atkinson, MD, MPH, IAC's associate director for immunization education, chooses a new Q&A to feature every week from a set of Q&As prepared by experts at CDC’s National Center for Immunization and Respiratory Diseases.

We hope you enjoy this feature and find it helpful when dealing with difficult real-life scenarios in your vaccination practice. Please encourage your healthcare professional colleagues to sign up to receive IAC Express at www.immunize.org/subscribe.

If you have a question for the CDC immunization experts, you can email them directly at nipinfo@cdc.gov. There is no charge for this service.

Related Links

Back to top

About IZ Express

IZ Express is supported in part by Grant No. 1NH23IP922654 from CDC’s National Center for Immunization and Respiratory Diseases. Its contents are solely the responsibility of Immunize.org and do not necessarily represent the official views of CDC.

IZ Express Disclaimer
ISSN 2771-8085

Editorial Information

  • Editor-in-Chief
    Kelly L. Moore, MD, MPH
  • Managing Editor
    John D. Grabenstein, RPh, PhD
  • Associate Editor
    Sharon G. Humiston, MD, MPH
  • Writer/Publication Coordinator
    Taryn Chapman, MS
    Courtnay Londo, MA
  • Style and Copy Editor
    Marian Deegan, JD
  • Web Edition Managers
    Arkady Shakhnovich
    Jermaine Royes
  • Contributing Writer
    Laurel H. Wood, MPA
  • Technical Reviewer
    Kayla Ohlde

This page was updated on .